Form 8-K TETRAPHASE PHARMACEUTICA For: Feb 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Tetraphase Pharmaceuticals (TTPH) PT Lowered to $6 at Stifel; Path Forward Complicated, But Still There
February 14, 2018 6:28 AM ESTStifel lowered its price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to $6.00 (from $13.00) while maintaining a Buy rating following the Phase 3 IGNITE3 trial failure.
Analyst Stephen Willey commented, "The failure of the P3 IGNITE3 trial to demonstrate the non-inferiority (NI) of intravenously-administered eravacycline vs.... More
